These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 10636722)

  • 1. [Individual therapeutic experiments. Ethical problems exemplified in oncology].
    Rippe KP
    Internist (Berl); 1999 Nov; 40(11):1243-6. PubMed ID: 10636722
    [No Abstract]   [Full Text] [Related]  

  • 2. The era of cancer discovery.
    Cantley LC; Baselga J
    Cancer Discov; 2011 Jun; 1(1):1. PubMed ID: 22586302
    [No Abstract]   [Full Text] [Related]  

  • 3. Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs.
    Amir E; Seruga B; Martinez-Lopez J; Kwong R; Pandiella A; Tannock IF; Ocaña A
    J Clin Oncol; 2011 Jun; 29(18):2543-9. PubMed ID: 21606435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Business barriers slowing the pace of cancer immunotherapy research and development.
    Tuma RS
    J Natl Cancer Inst; 2007 Nov; 99(21):1570-3. PubMed ID: 17971521
    [No Abstract]   [Full Text] [Related]  

  • 5. Multiple Dimensions of Value: Evaluative Frameworks for New Cancer Therapies.
    Cheung MC; Sabharwal M; Chambers A; Han D; Sabarre KA; Chan K
    J Clin Oncol; 2016 Apr; 34(12):1428-9. PubMed ID: 26884567
    [No Abstract]   [Full Text] [Related]  

  • 6. Critical role of phase I clinical trials in cancer treatment. American Society of Clinical Oncology.
    J Clin Oncol; 1997 Feb; 15(2):853-9. PubMed ID: 9053513
    [No Abstract]   [Full Text] [Related]  

  • 7. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Japanese universal health care faces a crisis in cancer treatment.
    Fujiwara Y; Yonemori K; Shibata T; Okita N; Ushirozawa N
    Lancet Oncol; 2015 Mar; 16(3):251-2. PubMed ID: 25752548
    [No Abstract]   [Full Text] [Related]  

  • 9. [Urogenital cancer studies in view of new legislation].
    Rohde D
    Urologe A; 2005 Mar; 44(3):294-6. PubMed ID: 15726310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluating the effectiveness of drugs. "The full potential of a therapy is often only clear after a number of years" (interview by Helmut Laschet)].
    Pfundner H
    MMW Fortschr Med; 2010 Dec; 152(51-52):10. PubMed ID: 21294362
    [No Abstract]   [Full Text] [Related]  

  • 11. Discontinued drugs in 2008: oncology drugs.
    Williams R
    Expert Opin Investig Drugs; 2009 Nov; 18(11):1581-94. PubMed ID: 19663760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Can new therapy concepts in oncology still be realized? Earlier death with standard therapy].
    Pickl S
    MMW Fortschr Med; 2002 Dec; 144(49):14. PubMed ID: 12577732
    [No Abstract]   [Full Text] [Related]  

  • 13. Should insurance be responsible for the cost of care while a patient is enrolled in a clinical trial?
    Weiss PA
    Clin J Oncol Nurs; 2008 Feb; 12(1):153-4. PubMed ID: 18258585
    [No Abstract]   [Full Text] [Related]  

  • 14. Obtaining financial support for patients receiving off-label drugs.
    Clancey JK; Card IC
    Oncol Nurs Forum; 2000 Jun; 27(5):769-70. PubMed ID: 10868389
    [No Abstract]   [Full Text] [Related]  

  • 15. [Clinical studies in oncology--a challenge for clinical and academic pathology].
    Röcken C
    Dtsch Med Wochenschr; 2013 May; 138(20):1073-6. PubMed ID: 23670265
    [No Abstract]   [Full Text] [Related]  

  • 16. [New therapeutic strategies in oncology].
    Bohuon C
    Ann Pharm Fr; 2010 Jul; 68(4):203-4. PubMed ID: 20637352
    [No Abstract]   [Full Text] [Related]  

  • 17. Ethical and financial considerations in third-party support of investigational cancer therapies.
    Young FE
    Cancer; 1993 Nov; 72(9 Suppl):2854-8. PubMed ID: 8402519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
    Takimoto CH
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Benefit-risk evaluation of new drugs as a basis for decisions on prioritization in hematology/oncology: methodical challenges and problem-solving strategies].
    Ludwig WD; Schildmann J
    Onkologie; 2011; 34 Suppl 1():6-10. PubMed ID: 21389762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The mandate for investigational cancer therapies.
    Brown E
    Physician Exec; 1995 Sep; 21(9):46-7. PubMed ID: 10151483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.